La vendita allo scoperto per IperionX dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di IperionX. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

IperionX (NASDAQ:IPX) Azioni, Report sulle vendite allo scoperto

IperionX Ltd produces titanium critical minerals, titanium powders, and titanium end products for various industries. The company's breakthrough titanium technologies have demonstrated the potential to produce titanium products that are sustainable, recyclable, and have low carbon intensity. IperionX is producing titanium metal powders from titanium scrap at its operational pilot facility in Utah, It also owns a titan critical minerals project, the Titan Project, covering over 11,000 acres of critical minerals that include titanium, rare earth elements, silica sand, and zircon in Tennessee, United States.

IperionX Limited - American Depositary Share

IperionX Ltd

Tachyon Protocol

Impax Asset Management Group PLC

Inpex Corp

INFLECTION PT ACQUISITION CORP II USD UNITS CONSISTING ONE CL A ORD SH & ONE-HALF OF ONE RED

Playtika Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.13 by 85.07 percent. This is a 91.3 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $696.000 million which missed the analyst consensus estimate of $706.030 million by 1.42 percent. This is a 11.00 percent increase over sales of $627.000 million the same period last year.

Earnings

Earnings Misses

News

PLTK

Playtika Holding Q2 Adj. EPS $0.02 Misses $0.13 Estimate, Sales $696.000M Miss $706.030M Estimate

Barclays analyst Julian Mitchell upgrades Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) from Underweight to Equal-Weight and raises the price target from $125 to $127.

Upgrades

Price Target

Analyst Ratings

Barclays Upgrades Emerson Electric to Equal-Weight, Raises Price Target to $127

ELAN

Elanco Animal Health Sees FY25 Adjusted EBITDA Of $850M-$890M, Which Includes Current Estimate For Net Tariff Impact Of $10M-$14M Versus $16M-$20M Previously

Hut 8 Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) reported quarterly earnings of $1.18 per share. The company reported quarterly sales of $41.299 million which missed the analyst consensus estimate of $49.700 million by 16.90 percent. This is a 17.28 percent increase over sales of $35.215 million the same period last year.

Hut 8 Mining Q2 2025 GAAP EPS $1.18, Sales $41.299M Miss $49.700M Estimate

Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 4.76 percent increase over losses of $(0.21) per share from the same period last year.

IMUX

Immunic Q2 EPS $(0.20) Misses $(0.17) Estimate

Somnigroup International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) raises FY2025 Adj EPS guidance from $2.30-$2.65 to $2.40-$2.70 vs $2.49 analyst estimate..

Guidance

Somnigroup International Raises FY2025 Adj EPS Guidance from $2.30-$2.65 to $2.40-$2.70 vs $2.49 Est

Somnigroup International Inc. Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.52 by 1.73 percent. The company reported quarterly sales of $1.881 billion which missed the analyst consensus estimate of $1.891 billion by 0.56 percent.

Earnings Beats

Somnigroup International Inc. Common Stock Q2 Adj. EPS $0.53 Beats $0.52 Estimate, Sales $1.881B Miss $1.891B Estimate

Barclays analyst Cecilia Romero Reyes upgrades BBVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBVA#NYSE">BBVA</a>) from Equal-Weight to Overweight.

BBVA

Barclays Upgrades BBVA to Overweight

Elanco Animal Health Says Fy25 Outlook Incorporates Current Estimate For Net Tariff Impact And Dynamic Landscape, More Than Offset By A 'Strong' First Half Performance And Foreign Exchange Tailwinds To Revenue

BCE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCE#NYSE">BCE</a>) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.51 by 9.8 percent. This is a 19.3 percent decrease over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $4.396 billion which beat the analyst consensus estimate of $4.320 billion by 1.76 percent. This is a 0.16 percent increase over sales of $4.389 billion the same period last year.

BCE Q2 Adj. EPS $0.46 Misses $0.51 Estimate, Sales $4.396B Beat $4.320B Estimate

P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.20 by 13.3 percent. This is a 4.17 percent decrease over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $72.704 million which beat the analyst consensus estimate of $71.250 million by 2.04 percent. This is a 2.29 percent increase over sales of $71.076 million the same period last year.

P10 Q2 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $72.704M Beat $71.250M Estimate

BCE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCE#NYSE">BCE</a>) raises FY2025 Adj EPS guidance from $1.84-$1.95 to $1.91-$1.98 vs $2.74 analyst estimate. Raises FY2025 sales outlook from $16.494 billion-$17.174 billion to $17.634 billion-$17.987 billion vs $24.206 billion estimate.

BCE Raises FY2025 Adj EPS Guidance from $1.84-$1.95 to $1.91-$1.98 vs $2.74 Est; Raises FY2025 Sales Guidance from $16.494B-$17.174B to $17.634B-$17.987B vs $24.206B Est

JP Morgan analyst Don Carducci downgrades Light &amp; Wonder (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) from Overweight to Neutral and lowers the price target from $108 to $95.

Downgrades

JP Morgan Downgrades Light & Wonder to Neutral, Lowers Price Target to $95

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) with a Buy and raises the price target from $20 to $22.

ARQT

Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $22

Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) FY2025 Revenue expected to be more than $2.30B vs $2.18B Est

AVAH

Aveanna Healthcare Hldgs FY2025  Revenue expected to be more than $2.30B vs $2.18B Est

Financial Guidance
The Company is updating its full-year 2025 financial guidance to tighten full-year 2025 reported, constant currency and organic constant currency1 revenue guidance and increase adjusted2 earnings per share financial guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">Projected Year Ending December 31, 2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Previous Guidance</td>
<td colspan="1" rowspan="1">Updated Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2025 Reported Revenue Change</td>
<td colspan="1" rowspan="1">5.7% - 8.2%</td>
<td colspan="1" rowspan="1">6.7%- 7.7%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Foreign Currency Exchange Impact</td>
<td colspan="1" rowspan="1">0.0% - 0.5%</td>
<td colspan="1" rowspan="1">0.5&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2025 Constant Currency Revenue Change</td>
<td colspan="1" rowspan="1">5.7% - 7.7%</td>
<td colspan="1" rowspan="1">6.2% - 7.2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2025 Organic Constant Currency Revenue Change(1)</td>
<td colspan="1" rowspan="1">3.0% - 5.0%</td>
<td colspan="1" rowspan="1">3.5% - 4.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Diluted EPS(2)</td>
<td colspan="1" rowspan="1">$7.90 - $8.10</td>
<td colspan="1" rowspan="1">$8.10 - $8.30</td>
</tr>
</tbody>
</table>
</figure>

Zimmer Biomet Holdings Raises FY2025 Adj EPS Guidance from $7.90-$8.10 to $8.10-$8.30 vs $7.97 Est; Narrows FY2025 Sales Guidance from $8.117B-$8.309B to $8.190B-$8.270B vs $8.184B Est

Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) is looking for Q3 Adj EPS of $0.12-$0.16 vs $0.13 analyst estimate. sees sales of $1.080 billion-$1.110 billion vs $1.083 billion analyst estimate.

Elanco Animal Health Sees Q3 Adj EPS $0.12-$0.16 vs $0.13 Est; Sees Sales $1.080B-$1.110B vs $1.083B Est

BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) narrows FY2025 Adj EPS guidance from $2.65-$2.80 to $2.65-$2.74 vs $2.45 analyst estimate. Raises FY2025 sales outlook from $23.677 billion-$24.653 billion to $24.409 billion-$24.897 billion vs $21.597 billion estimate.

TSX:BCE

BCE Narrows FY2025 Adj EPS Guidance from $2.65-$2.80 to $2.65-$2.74 vs $2.45 Est; Raises FY2025 Sales Guidance from $23.677B-$24.653B to $24.409B-$24.897B vs $21.597B Est

Hut 8 Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HUT#TSX">HUT</a>) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $(0.15) by 886.67 percent. This is a 251.28 percent increase over losses of $(0.78) per share from the same period last year. The company reported quarterly sales of $41.299 million which missed the analyst consensus estimate of $49.000 million by 15.72 percent. This is a 17.28 percent increase over sales of $35.215 million the same period last year.

TSX:HUT

Hut 8 Mining Q2 EPS $1.18 Beats $(0.15) Estimate, Sales $41.299M Miss $49.000M Estimate

WIIM

Becton, Dickinson shares are trading higher after the company reported better-than-expected Q3 adjusted EPS and sales. The company also raised FY25 EPS guidance.

Press Releases

IperionX Letter to Shareholders

IperionX Awarded $47.1M by the U.S. DoD to Secure U.S. Titanium Supply Chains

IperionX Enhances Board With Appointment of Senior U.S. Directors

IperionX Interim Financial Report for the Six Months Ended December 31, 2024

IperionX Receives U.S. EXIM Bank Board Approval for a $11M Loan to Produce "All-American" Titanium Products

IperionX Commences Titan Critical Minerals Project Definitive Feasibility Study With U.S. Government Support

IperionX – March 2025 Quarterly Report

Contracts

IperionX Awarded U.S. Department of Defense SBIR Phase III Contract for Up to US$99M

IperionX Secures First U.S. Army Task Order Under US$99 Million SBIR Phase III Contract

IperionX – June 2025 Quarterly Report

American Battery Technology Company - Common Stock

American Battery Tech

BHP Group Limited American Depositary Shares (Each representing two Ordinary Shares)

Comments

IperionX

Vendite allo scoperto

IperionX (NASDAQ:IPX) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO